查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2016883

经导管栓塞和闭塞装置市场：按产品类型、材料、技术、应用和最终用户分類的全球市场预测，2026-2032年

Transcatheter Embolization & Occlusion Device Market by Product Type, Material, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，经导管栓塞和闭塞装置市场价值将达到 58.9 亿美元，到 2026 年将成长至 63.3 亿美元，到 2032 年将达到 103.3 亿美元，复合年增长率为 8.34%。

主要市场统计数据
基准年 2025 58.9亿美元
预计年份：2026年 63.3亿美元
预测年份 2032 103.3亿美元
复合年增长率 (%) 8.34%

策略性地引入经导管栓塞/闭塞装置，使其成为微创血管治疗发展的关键驱动力。

经导管栓塞和闭塞装置结合了先进的材料科学和精准的输送系统，已成为微创血管治疗转型过程中不可或缺的基础工具。这些装置旨在阻断各种临床适应症中的病理性血流，并与介入放射学、血管外科和血管内神经外科的工作流程紧密结合。该领域的特点是临床上对兼具疗效、输送精准性和可预测生物相容性的装置的需求日益增长。随着临床医师越来越重视缩短门诊时间和手术时间，装置设计者正积极研发创新技术，以简化操作、提高影像清晰度并增强部署过程中的控制。

生物材料、输送系统和手术流程的最新进展正在从根本上改变栓塞术的临床实践和商业策略。

栓塞和闭塞装置领域正经历着变革性的转变，这主要得益于生物材料、输送系统和手术技术的进步。材料科学的突破性进展催生了新一代液体栓塞剂和微球，这些栓塞剂和微球具有更可预测的聚合特性、更强的渗透性和可调控的吸收特性，从而拓展了治疗选择并提高了安全性。同时，包括血管栓塞器和可移除弹簧圈在内的机械闭塞技术也在不断改进，以平衡血栓形成和血管保护，从而为各种不同的解剖结构挑战提供量身定制的解决方案。

对不断变化的贸易政策如何重塑栓塞器械利害关係人的采购、製造决策和市场进入进行全面评估。

美国近期加征的关税令全球医疗设备供应链更加复杂，对製造商、经销商和医疗保健系统产生了连锁反应。这些关税改变了零件采购和成品进口的成本计算方式，可能促使企业进行策略调整，例如改变组装流程、选择替代供应商或加强垂直整合，以维持获利能力和前置作业时间的连续性。对于依赖跨境采购特殊聚合物、金属、微导管组件和成像标记的企业而言，由于供应商需要重新考虑运输路线和库存策略，这些政策变化可能导致交货週期延长。

一项实用的細項分析，展示了产品类型、材料和技术如何与临床用例和医疗保健环境相互作用，以及这些因素如何影响产品的采用。

详细的細項分析揭示了不同产品类型、材料、技术、临床应用和医疗环境中的性能驱动因素和应用障碍，这些因素决定了製造商和医疗系统的策略重点。在产品类型中，栓塞弹簧圈（有可脱卸式和推入式两种配置）仍然是靶向机械闭塞的关键，因为其放置精度至关重要。同时，液体栓塞剂（包括乙烯 - 乙烯醇和N-丁基氰基丙烯酸酯配方）为复杂的血管床提供了高度灵活的选择。微球和颗粒栓塞剂可实现精确闭塞并具有可预测的远端渗透性，而血管栓塞器则可在特定解剖结构中实现快速近端闭塞。每种产品组都有其独特的操作特性、影像可见度以及操作者熟练度曲线，这些都会影响其在临床路径中的应用。

富有洞察力的区域观点突显了主要区域在监管、报销和临床引入方面的差异如何影响战略市场方法。

区域趋势对临床实务模式、报销架构和供应链结构有显着影响，导致各大区域的优先事项有所不同。在美洲，临床医生通常优先考虑快速完成治疗和便于门诊就诊的解决方案，因此，能够提高工作流程效率和提供全面培训支援的医疗器材备受关注。该地区的监管路径和支付方结构促使製造商证明其产品的临床疗效和经济价值，从而影响实证策略和商业性通讯。

检验了竞争动态、产品创新、证据产生和通路策略如何决定医疗设备製造商的市场定位。

栓塞和闭塞器材领域的竞争动态由产品创新、临床证据、服务交付和通路关係等因素共同塑造。主要企业透过对下一代材料、改进剂量方案和增强与影像诊断的兼容性进行针对性投资来脱颖而出，同时优先考虑临床医生培训和治疗结果追踪。器械製造商与学术机构和临床网络之间的伙伴关係对于产生高品质的真实世界证据以及与介入团队建立长期信任关係变得日益重要。

为製造商提供可操作且优先考虑的建议，以协调产品创新、临床证据和商业性成功，从而加速产品推广。

产业领导企业应推动一系列合作倡议，协调产品开发、临床证据目标和商业性执行，以实现栓塞治疗的长期价值。优先考虑模组化设计以及与常用微导管平台的兼容性，以减少手术操作的阻力，并扩大其在多种适应症中的临床应用范围。投资研发差异化的生物材料和成像标记物，以改善药物传输控制和视觉化效果。这些技术差异化可以透过结构完善的研究和註册登记转化为可证实的临床效益。

采用透明的混合方法研究途径，结合临床证据审查、专家访谈和同行检验，以确保获得可靠且实用的见解。

本研究整合了同侪审查的临床文献、医疗设备监管申报文件、卫生监管机构的指导文件、对介入医师和采购经理的访谈，以及对製造商技术规范的系统性回顾，旨在全面了解栓塞和闭塞器。资料收集强调可重复性和资讯来源三角验证，将关键意见领袖（KOL）的定性见解与从公开的监管申报文件和医师主导的註册研究中提取的器械性能特征相结合。受访者的选择涵盖了不同的临床专科、临床环境和地理区域，以全面了解有关手术选择和应用的考量。

整合各项结论，重点阐述决定哪些技术将被广泛采用的临床、营运和策略要求。

经导管栓塞和闭塞装置处于临床需求、材料创新和系统层面经济考量交会的战略要地。定义该领域的技术日趋成熟，这要求製造商在拓展临床应用范围的同时，也要在不同的医疗环境中展现出可验证的价值。商业化的成功取决于能否平衡产品性能与实际应用因素，例如培训、影像相容性和供应链韧性。此外，贸易和政策的变化凸显了敏捷的生产和采购计画的重要性，即使面临外部衝击，也能确保器械供应。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 经导管栓塞及闭塞装置市场：依产品类型划分

  • 栓塞线圈
    • 可拆卸线圈
    • 推式线圈
  • 液态栓塞剂
    • 乙烯-乙烯醇共聚物
    • N-丁基氰基丙烯酸酯
  • 微球
  • 颗粒栓子
  • 血管栓塞

第九章 经导管栓塞及闭塞装置市场：依材料划分

  • 生物基材料
  • 合成材料

第十章：经导管栓塞及闭塞装置市场：依技术划分

  • 血流导栓塞术
  • 机械性闭塞
  • 微导管输送系统

第十一章 经导管栓塞与闭塞装置市场：依应用划分

  • 出血控制
  • 肝动脉栓塞术
  • 神经血管栓塞术
  • 週边血管栓塞
  • 子宫肌瘤栓塞术

第十二章 经导管栓塞和闭塞装置市场：依最终用户划分

  • 门诊手术中心
  • 医院
  • 专科诊所

第十三章 经导管栓塞及闭塞装置市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 经导管栓塞及闭塞装置市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 经导管栓塞和闭塞装置市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国经导管栓塞、闭塞装置市场

第十七章：中国经导管栓塞和闭塞装置市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AngioDynamics, Inc.
  • B. Braun Melsungen AG
  • Boston Scientific Corporation
  • Cook Medical LLC
  • Edwards Lifesciences Corporation
  • Johnson & Johnson
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Penumbra, Inc.
  • Terumo Corporation
  • WL Gore & Associates, Inc.
Product Code: MRR-03168519576B

The Transcatheter Embolization & Occlusion Device Market was valued at USD 5.89 billion in 2025 and is projected to grow to USD 6.33 billion in 2026, with a CAGR of 8.34%, reaching USD 10.33 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.89 billion
Estimated Year [2026] USD 6.33 billion
Forecast Year [2032] USD 10.33 billion
CAGR (%) 8.34%

A strategic introduction framing transcatheter embolization and occlusion devices as pivotal drivers of minimally invasive vascular therapy evolution

Transcatheter embolization and occlusion devices have emerged as foundational tools within the broader shift toward less invasive vascular therapies, integrating advanced materials science with precision delivery systems. These devices are engineered to occlude pathological blood flow across a diverse set of clinical indications, and they intersect with interventional radiology, vascular surgery, and endovascular neurosurgery workflows. The landscape is characterized by escalating clinical demand for options that combine efficacy, delivery accuracy, and predictable biocompatibility. As clinicians increasingly prioritize outpatient pathways and shorter procedural times, device designers are responding with innovations that streamline handling, enhance visibility under imaging, and improve controllability during deployment.

The evolution of device form factors has expanded therapeutic reach beyond traditional applications such as hemorrhage control and uterine fibroid embolization to embrace hepatic, peripheral vascular, and neurovascular interventions. Concurrently, procedural teams are integrating microcatheter technologies and hybrid delivery strategies to navigate complex anatomy and achieve durable occlusion. Regulatory authorities continue to refine pathways for minimally invasive solutions, prompting manufacturers to address both clinical evidence generation and post-market surveillance. Taken together, these forces are reshaping clinical algorithms and commercial models, demanding closer alignment among R&D, clinical affairs, and market access functions to ensure that new products deliver measurable improvements in patient outcomes and operational efficiency.

How recent advances in biomaterials, delivery systems, and procedural workflows are fundamentally reshaping clinical practice and commercial strategies in embolization

The landscape for embolization and occlusion devices is in the midst of transformative shifts driven by converging advances in biomaterials, delivery systems, and procedural practice. Material science breakthroughs are enabling next-generation liquid embolics and microspheres that offer more predictable polymerization, enhanced radiopacity, and tunable resorption profiles, thereby widening therapeutic options and improving safety margins. At the same time, mechanical occlusion technologies including vascular plugs and detachable coils are being refined to balance thrombogenicity with vessel preservation, enabling tailored solutions for diverse anatomic challenges.

Parallel improvements in microcatheter design and flow-directed delivery systems are lowering procedural complexity and increasing the precision of agent deployment. These technological gains are amplified by enhanced imaging modalities and intra-procedural guidance tools that together reduce device migration risk and improve occlusion completeness. In practice, clinicians are adopting multimodal strategies-combining devices and materials across platforms-to achieve durable outcomes in complex cases. Commercially, these technical evolutions are prompting value-based conversations with health systems that emphasize total cost of care, procedural throughput, and long-term clinical durability rather than device price alone. Consequently, manufacturers are recalibrating portfolio strategies to prioritize interoperability, training support, and evidence generation that demonstrate real-world clinical and economic benefits.

Comprehensive appraisal of how evolving trade policies are reshaping procurement, manufacturing decisions, and market access for embolization device stakeholders

Recent tariff measures originating from the United States have injected fresh complexity into global supply chains for medical devices, with cascading implications for manufacturers, distributors, and health systems. Tariffs alter the cost calculus of component sourcing and finished goods imports, which can prompt strategic shifts such as relocating assembly operations, qualifying alternative suppliers, or increasing vertical integration to preserve margin and supply continuity. For companies reliant on cross-border procurement of specialized polymers, metals, microcatheter components, and imaging-compatible markers, these policy changes can increase lead times as vendors reassess routing and inventory policies.

The cumulative operational impact extends beyond unit costs. Procurement teams are adjusting contract terms and inventory strategies to buffer against tariff volatility, while regulatory and quality functions must revalidate device configurations when manufacturing locations or component suppliers change. Clinicians and hospital purchasers may encounter altered pricing dynamics or phased product introductions as manufacturers prioritize allocations to markets with more favorable trade terms. Moreover, tariff-driven supply rebalancing can accelerate regionalization of manufacturing, encouraging companies to co-locate production nearer to end markets to reduce trade exposure. As a result, strategic planning now requires integrated scenario modeling across procurement, regulatory, and commercial teams to ensure uninterrupted access to critical embolization and occlusion technologies and to protect clinical continuity.

Actionable segmentation intelligence showing how product types, materials, and technologies interplay with clinical use cases and care settings to shape adoption

Deep segmentation analysis reveals distinct performance drivers and adoption barriers across product categories, materials, technologies, clinical applications, and care settings that determine strategic priorities for manufacturers and health systems. Within product types, embolization coils-available as detachable and pushable configurations-remain integral for targeted mechanical occlusion where placement precision is paramount, while liquid embolic agents, including ethylene vinyl alcohol copolymer and N-butyl cyanoacrylate formulations, provide conformable options for complex vascular beds. Microspheres and particulate embolic agents offer calibrated occlusion with predictable distal penetration, and vascular plugs deliver rapid proximal vessel occlusion for certain anatomies. Each product class carries unique handling characteristics, imaging visibility profiles, and operator learning curves that influence clinical pathway adoption.

Material selection further differentiates device performance, as biological agents often emphasize biocompatibility and resorption dynamics, while synthetic agents provide consistency and longer-term permanence. Technology modalities-flow-directed embolization, mechanical occlusion, and microcatheter delivery systems-interact with device choice to optimize procedural efficiency and outcome durability across indications. Clinical applications span hemorrhage control, hepatic embolization, neurovascular interventions, peripheral vascular occlusions, and uterine fibroid embolization, many of which place divergent demands on device flexibility, occlusion permanence, and embolic particle behavior. Finally, end user environments such as ambulatory surgical centers, hospitals, and specialty clinics influence purchasing protocols, inventory management, and training investments, with each setting requiring tailored product configurations and service models. Integrated segmentation insight therefore supports targeted product development, differentiated clinical training, and value propositions that align with specific procedural workflows and institutional procurement criteria.

Insightful regional perspectives highlighting how regulatory, reimbursement, and clinical adoption differences across major territories shape strategic market approaches

Regional dynamics exert a powerful influence on clinical practice patterns, reimbursement frameworks, and supply chain architectures, resulting in divergent priorities across major geographies. In the Americas, clinician demand often favors rapid procedural turnaround and outpatient-capable solutions, prompting emphasis on devices that facilitate efficient workflows and strong training support. Regulatory pathways and payer structures in this region pressure manufacturers to demonstrate both clinical efficacy and economic value, which in turn shapes evidence generation strategies and commercial messaging.

Across Europe, the Middle East & Africa, the market environment is fragmented by heterogeneous reimbursement policies, variable infrastructure, and diverse clinical guidelines. This creates opportunities for regionally adapted product portfolios and collaborative partnerships that address local training needs and procurement cycles. In Asia-Pacific, rapid investments in interventional capacity and emerging centers of excellence are expanding the clinical footprint for embolization therapies. Supply chain localization and strategic alliances with regional distributors are often prioritized to accelerate access, while product adaptations may be needed to match procedural preferences and device registration requirements. Ultimately, each region presents unique trade-offs between regulatory complexity, cost sensitivities, and clinical adoption velocities, requiring manufacturers to deploy differentiated market entry strategies and to invest in local evidence and training programs to achieve sustained uptake.

Examination of competitive dynamics and how product innovation, evidence generation, and channel strategies determine market positioning for device manufacturers

Competitive dynamics in the embolization and occlusion device arena are driven by a combination of product innovation, clinical evidence, service offerings, and channel relationships. Leading companies differentiate through targeted investments in next-generation materials, improved delivery profiles, and enhanced imaging compatibility, while also prioritizing clinician training and outcomes tracking. Partnerships between device manufacturers and academic centers or clinical networks are increasingly important for generating high-quality real-world evidence and building long-term credibility with interventional teams.

At the go-to-market level, distributors, strategic alliances, and direct sales models each offer distinct advantages depending on the therapeutic area and end user target. Companies that pair product innovation with comprehensive training curricula and robust post-market surveillance tend to foster stronger clinician loyalty and faster uptake. Moreover, firms that can demonstrate interoperability with existing catheter platforms and imaging systems reduce procedural friction and accelerate adoption. Competitive positioning also depends on the ability to navigate procurement preferences in hospitals and ambulatory centers, and to present clear value propositions that align with both clinical outcomes and operational efficiencies. Collectively, these factors create a landscape where nimble innovators and established incumbents must continually refine their offerings to sustain leadership.

Practical and prioritized recommendations for manufacturers to align product innovation, clinical evidence, and commercial execution to accelerate adoption

Industry leaders should pursue a coordinated set of actions that align product development, clinical evidence objectives, and commercial execution to capture long-term value in embolization therapies. Prioritize modular design and compatibility with commonly used microcatheter platforms to reduce procedural friction and to broaden clinical applicability across multiple indications. Invest in differentiated biomaterials and imaging markers that enhance delivery control and visualization; these technical distinctions can be translated into demonstrable clinical benefits through well-structured studies and registries.

Strengthen partnerships with clinical centers to co-develop training programs that accelerate operator proficiency and reduce variability in outcomes. Simultaneously, reassess supply chain footprints to mitigate exposure to tariff-driven disruptions and to ensure redundancy for critical components. Expand payer engagement to articulate total cost of care benefits, focusing on metrics such as procedural time, complication reduction, and downstream resource utilization. Finally, tailor commercial approaches to regional and facility-level nuances by offering flexible contracting, local evidence packages, and integrated post-sales support. By taking these integrated steps, companies can reduce adoption barriers, differentiate in competitive procurement environments, and demonstrate measurable improvements in both clinical and economic outcomes.

Transparent mixed-methods research approach combining clinical evidence review, expert interviews, and cross-validation to ensure robust actionable insights

This research synthesizes peer-reviewed clinical literature, device regulatory filings, guidance documents from health authorities, primary interviews with interventional clinicians and procurement leaders, and a structured review of manufacturer technical specifications to create a comprehensive understanding of embolization and occlusion device dynamics. Data collection emphasized reproducibility and source triangulation, combining qualitative insights from key opinion leaders with device performance characteristics extracted from publicly available regulatory submissions and physician-led registries. Interview subjects were selected to reflect a diversity of clinical specialties, practice settings, and geographic regions to capture the breadth of procedural preferences and adoption considerations.

Analytical methods included thematic coding of interview transcripts to identify recurring barriers and enablers, cross-comparison of device feature sets to assess technological differentiation, and scenario analysis to explore supply chain and policy-driven contingencies. All findings were validated through iterative expert review and reconciled against clinical guidelines and published safety reports. Where manufacturer-provided claims were considered, they were corroborated with independent clinical evidence and regulatory summaries to ensure balanced interpretation. The methodology intentionally avoided reliance on single-source commercial data, favoring mixed-methods synthesis to provide robust, actionable insights for R&D, clinical affairs, and commercial leadership.

Concluding synthesis emphasizing clinical, operational, and strategic imperatives that will determine which technologies achieve widespread adoption

Transcatheter embolization and occlusion devices occupy a strategic nexus of clinical need, materials innovation, and system-level economic considerations. The techniques and technologies that define this field are maturing in ways that expand clinical applicability while simultaneously increasing demands on manufacturers to deliver demonstrable value across diverse care settings. Successful commercialization will hinge on an ability to reconcile product performance with pragmatic deployment factors such as training, imaging compatibility, and supply chain resilience. Moreover, trade and policy shifts underscore the importance of agile manufacturing and procurement planning to sustain device availability in the face of external shocks.

For stakeholders across the ecosystem, the path forward is clear: invest in clinical partnerships to build high-quality evidence, prioritize modular and interoperable device designs to reduce procedural friction, and align commercial models with regional healthcare realities. By doing so, companies and health systems can accelerate safe adoption, improve patient outcomes, and enhance procedural efficiency. The collective focus on these priorities will determine which innovations translate into standard practice and which remain niche interventions, shaping the future of minimally invasive vascular care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transcatheter Embolization & Occlusion Device Market, by Product Type

  • 8.1. Embolization Coils
    • 8.1.1. Detachable Coils
    • 8.1.2. Pushable Coils
  • 8.2. Liquid Embolic Agents
    • 8.2.1. Ethylene Vinyl Alcohol Copolymer
    • 8.2.2. N-Butyl Cyanoacrylate
  • 8.3. Microspheres
  • 8.4. Particulate Embolic Agents
  • 8.5. Vascular Plugs

9. Transcatheter Embolization & Occlusion Device Market, by Material

  • 9.1. Biological Agents
  • 9.2. Synthetic Agents

10. Transcatheter Embolization & Occlusion Device Market, by Technology

  • 10.1. Flow Directed Embolization
  • 10.2. Mechanical Occlusion
  • 10.3. Microcatheter Delivery Systems

11. Transcatheter Embolization & Occlusion Device Market, by Application

  • 11.1. Hemorrhage Control
  • 11.2. Hepatic Embolization
  • 11.3. Neurovascular Embolization
  • 11.4. Peripheral Vascular Embolization
  • 11.5. Uterine Fibroid Embolization

12. Transcatheter Embolization & Occlusion Device Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Transcatheter Embolization & Occlusion Device Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Transcatheter Embolization & Occlusion Device Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Transcatheter Embolization & Occlusion Device Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Transcatheter Embolization & Occlusion Device Market

17. China Transcatheter Embolization & Occlusion Device Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AngioDynamics, Inc.
  • 18.6. B. Braun Melsungen AG
  • 18.7. Boston Scientific Corporation
  • 18.8. Cook Medical LLC
  • 18.9. Edwards Lifesciences Corporation
  • 18.10. Johnson & Johnson
  • 18.11. Medtronic plc
  • 18.12. Merit Medical Systems, Inc.
  • 18.13. Penumbra, Inc.
  • 18.14. Terumo Corporation
  • 18.15. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY DETACHABLE COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY DETACHABLE COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY DETACHABLE COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PUSHABLE COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PUSHABLE COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PUSHABLE COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROSPHERES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROSPHERES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROSPHERES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY VASCULAR PLUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY VASCULAR PLUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY VASCULAR PLUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY BIOLOGICAL AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY BIOLOGICAL AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY BIOLOGICAL AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SYNTHETIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SYNTHETIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SYNTHETIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY FLOW DIRECTED EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY FLOW DIRECTED EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY FLOW DIRECTED EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MECHANICAL OCCLUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MECHANICAL OCCLUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MECHANICAL OCCLUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROCATHETER DELIVERY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROCATHETER DELIVERY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROCATHETER DELIVERY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEMORRHAGE CONTROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEMORRHAGE CONTROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEMORRHAGE CONTROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEPATIC EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEPATIC EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEPATIC EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY UTERINE FIBROID EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY UTERINE FIBROID EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY UTERINE FIBROID EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GCC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 152. GCC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 153. GCC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 154. GCC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. GCC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. GCC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. G7 TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 176. G7 TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 177. G7 TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 178. G7 TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. G7 TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. G7 TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. NATO TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 184. NATO TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 185. NATO TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 186. NATO TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. NATO TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. NATO TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)